TTrialPathMatch Me to Trials
← Back to trials
RecruitingEndogenous Cushing SyndromeAdrenal InsufficiencyHypercortisolism

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

Eligible age

18–75 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace approach). The investigators are also evaluating new biomarker steroids to reflect adequate osilodrostat dosing, the durability and safety, and clinical improvement during treatment.

Sponsor: University of Michigan

You may qualify if…

  • ✓ Endogenous Cushing syndrome, either following surgery or not candidates for surgery
  • ✓ Under consideration to receive osilodrostat as part of their clinical care
  • ✓ Able to provide informed consent.

You may not qualify if…

  • ✕ Treatment with other investigational drugs within 30 days or five half-lives (whichever is longer).
  • ✕ A history of hypersensitivity to osilodrostat or therapies of a similar chemical class.

Where it's recruiting

Michigan

Ann Arbor

Source: ClinicalTrials.gov · NCT06430528 · last updated 2026-09-09